Featured News
AIM Blog
A Love Rekindled Through Loss, United in Purpose
This article originally appeared in the 2026 Impact Report. Become a member today to get access to additional exclusive content, meetings and insights into the Alzheimer's and dementia public policy c...
All News
AIM Blog
A Look Back on the 117th Congress’ Actions to Address Alzheimer’s and Dementia
Thanks to our hardworking advocates and congressional champions, critical bipartisan policy priorities to address Alzheimer’s and dementia across the nation...
Press Release
Critical Alzheimer’s and Dementia Priorities Signed Into Law
Washington, D.C., December 29, 2022 – The Alzheimer’s Association and the Alzheimer’s Impact Movement (AIM) commend the passage of the...
Press Release
Congress Prioritizes Addressing Alzheimer’s and Dementia
Key provisions of the ENACT Act, language to strengthen FDA accelerated approval pathway, a $226 million increase for Alzheimer’s and...
Press Release
Alzheimer’s Association Calls on CMS to Reverse Its Decision to Severely Limit Access to FDA-Approved Alzheimer’s Disease Treatments
Association Files Formal Request for Reconsideration of National Coverage Determination for Monoclonal Antibodies Directed Against Amyloid for the Treatment of...
AIM Blog
Alzheimer’s Association Hosts Inaugural State Dementia Services Coordinator Summit
At the end of October, the Alzheimer’s Association hosted the inaugural State Dementia Services Coordinator (DSC) Summit in Washington, D.C...
Press Release
Alzheimer’s Association Statement On Gantenerumab Phase 3 Topline Data Release
Chicago, November 14, 2022 — The Alzheimer’s Association is disappointed by the topline Phase 3 data reported today by Genentech...